Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
TBE Meningococcal Disease Influenza Smallpox
 
Publications

  Meningococcal Vaccines

6. Richmond P, Borrow R, Findlow J, Martin S, Thornton C, Cartwright K, Miller E.
Evaluation of De-O-Acetylated Meningococcal C Polysaccharide-Tetanus Toxoid Conjugate Vaccine in Infancy: Reactogenicity, Immunogenicity, Immunologic Priming, and Bactericidal Activity against O-Acetylated and De-O-Acetylated Serogroup C Strains.
Immunisation Division, Communicable Disease Surveillance Centre, Public Health Laboratory Service, London NW9 5EQ, United Kingdom.
Infect Immun 2001 Apr;69(4):2378-82

7. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, Cartwright K, Miller E.
Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.
Immunisation Division, Communicable Disease Surveillance Centre, Public Health Laboratory Service, London, United Kingdom.
J Infect Dis 2001 Jan 1;183(1):160-3

8. Richmond P, Borrow R, Miller E, et al.
Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory.
J Infect Dis 1999; 179:1569-72.

9. Richmond P, Goldblatt D, Fusco PC, et al.
Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults.
Vaccine 18:641-646; 1999.

10. Richmond P, Borrow R, Clark S, Findlow J, Morris R, and Cartwright K. 1999.
Meningococcal C-tetanus toxoid conjugate vaccine is immunogenic and induces memory in infants.
Abstract O-13, p. 29, Abstract Book of the 17th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID); Heraklion, Crete, Greece; May 19-21, 1999.

11. Borrow R, Fox AJ, Richmond P, et al. 2000.
Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine.
Epidemiol. Infect. 124: 427-32.

12. Richmond P, Cartwright K, Borrow R, Morris R, Clark S, Burrage M, Thornton C, Kaczmarski E, Miller E. 1998.
An investigation of the immunogenicity and reactogenicity of three meningococcal serogroup C conjugate vaccines administered as a single dose in UK toddlers.
p. 153. In X. Nassif, M.-J. Quentin-Millet, & M.-K. Taha (eds.), Abstracts of the Eleventh International Pathogenic Neisseria Conference (Neisseria 98, Nice, France, Nov. 1-6, 1998).

13. Richmond P, Goldblatt D, Heron I, Fusco JDS, Fusco PC, Michon F. 1998.
Quantitative and qualitative evaluation of a new meningococcal C conjugate vaccine.
Abstract PS 8, p. 10, Abstract Book of the 16th Annual Meeting of the European Society for Pediatric Infectious Diseases (ESPID); Bled, Slovenia; May 27-29, 1998.

14. McDonald NE, Halperin SA, Law BJ, et al.
Induction of immunologic memory by conjugated vs. plain meningococcal C polysaccharide vaccine in toddlers.
JAMA 1998; 280:1685-1689.

15. Richmond P, Goldblatt D, Fusco PC, Fusco JDS, Heron I, Michon F. 1997.
Phase I evaluation of a meningococcal C-tetanus toxoid conjugate vaccine.
Abstract G-111, p. 212, American Society for Microbiology, 37th ICAAC (Toronto, Ontario, Canada, 1997), Washington, D.C.

16. MacLennan J, Shackley F, Health P et al.
Induction of immunologic memory by Neisseria meningitidis group C conjugate vaccine.
Paper presented at 15th Annual Meeting of the European Society for Paediatric Infections May 21-23, 1997; Paris, France.

17. Hronowski L, Di J, Pullen J, Rohrbaugh J, Huang C-H, Michon F, Mates S, Tai JY. 1993.
Structure activity studies on Neisseria meningitidis group C polysaccharide-protein conjugate vaccines - the effect of O-acetylation on the nature of the antibody response.
Abstract E-75, p.155, American Society for Microbiology, 93rd General Meeting (Atlanta, GA, 1993), Washington, D.C.

18. Jones, DM.
Meningococcal vaccines.
J Med Microbiol 1993, 38:77-78.

19. Pullen J, Michon F, Demuys J-M, Huang C, Hoskin S, Jennings HJ, Tai JY. 1992.
Comparison of the immunogenicity of Neisseria Meningitidis group C polysaccharide-protein conjugate vaccines.
Abstract 1288, p. 74, American Society for Microbiology, 32nd ICAAC (Anaheim, CA, 1997), Washington, D.C.

20. Arakere G, Frasch CE.
Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers.
Infect. Immun. 59:4349-4356;1991

21. Peltola H., A. Safary, H. Kayhty, V. Karanko, F.E., Andre. 1985.
Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl negative and O-acetyl positive serogroup C polysaccharides.
Pediatrics 76:91-96.

22. Gotschlich EC.
The status of vaccines to meningococcal and gonococcal disease.
Ann Inst Pasteur/Microbiol 1985; 136B:341-355.

23. Jennings HJ, Lugowski C. 1981.
Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates.
J. Immunol. 127:1011-1018.

24. Steinhoff, M.C, E.B. Lewin, E.C. Gotschlich, J.B. Robbins, and Panorama Pediatric Group. 1981.
Group C Neisseria meningitidis variant polysaccharide vaccines in children.
Infect. Immun. 34:144-146.

25. Glode MP, E.B. Lewin, A. Sutton, C.T. Le, E.C. Gotschlich, and J.B. Robbins. 1979.
Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl positive and O-acetyl negative variants and Escherichia coli K92 in adult volunteers.
J. Infect. Dis. 139:52-59.



 » Printversion

 
 
  » find


 

Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
» read more

Baxter receives preparedness contract from Austrian Ministry of Health for Pandemic Influenza Vaccine
» read more

Baxter Announces Safety and Immunogenicity Results from Phase I/II Clinical Trial of Cell-Based Candidate H5N1 Pandemic Vaccine
» read more

 
Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,